TY - JOUR T1 - Human C-C chemokine receptor 3 monoclonal antibody inhibits pulmonary inflammation in allergic mice. AU - Wang,Kai, AU - Shen,Hua-hao, AU - Li,Wen, AU - Huang,Hua-qiong, PY - 2007/10/26/pubmed PY - 2009/5/13/medline PY - 2007/10/26/entrez SP - 1791 EP - 6 JF - Acta pharmacologica Sinica JO - Acta Pharmacol Sin VL - 28 IS - 11 N2 - AIM: To evaluate the effect of C-C chemokine receptor 3 (CCR3) blockade on pulmonary inflammation and mucus production in allergic mice. METHODS: We used the synthetic peptide of the CCR3 NH2-terminal as the immunizing antigen and generated murine monoclonal antibody against the human CCR3. In addition, the generated antibody was administered to mice sensitized and challenged with ovalbumin. The inflammatory cells in bronchoalveolar lavage, cytokine levels, pulmonary histopathology, and mucus secretion were examined. RESULTS: The Western blotting analysis indicated that the generated antibody bound to CCR3 specifically. The allergic mice treated with the antihuman CCR3 antibody exhibited a significant reduction of pulmonary inflammation accompanied with the alteration of cytokine. CONCLUSION: The antibody we generated was specific to CCR3. The inhibition of airway inflammation and mucus overproduction by the antibody suggested that the blockade of CCR3 is an appealing therapeutical target for asthma. The present research may provide an experimental basis for the further study of this agent. SN - 1671-4083 UR - https://www.unboundmedicine.com/medline/citation/17959030/Human_C_C_chemokine_receptor_3_monoclonal_antibody_inhibits_pulmonary_inflammation_in_allergic_mice_ L2 - https://doi.org/10.1111/j.1745-7254.2007.00635.x DB - PRIME DP - Unbound Medicine ER -